Arrowhead Pharmaceuticals, Inc.
ARWR
$55.05
$0.040.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 229.73% | 86.45% | -147.31% | 314.02% | -1.49% |
| Total Depreciation and Amortization | 0.06% | 2.62% | 2.28% | 16.22% | 4.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -50.05% | 136.27% | -15.11% | 30.95% | 42.64% |
| Change in Net Operating Assets | -61.09% | -113.59% | -139.45% | 711.90% | -193.56% |
| Cash from Operations | -34.21% | 113.24% | -133.63% | 414.52% | -6.60% |
| Capital Expenditure | 71.32% | -216.79% | 55.37% | 29.52% | 69.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -126.96% | -44.27% | 134.65% | -591.46% | 142.50% |
| Cash from Investing | -132.69% | -48.64% | 133.65% | -646.37% | 134.50% |
| Total Debt Issued | -- | -55.45% | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 67.02% | -- | -- |
| Issuance of Common Stock | 10,142.60% | 127.35% | -99.91% | 38,386.91% | 184.30% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -100.00% | 738.16% |
| Cash from Financing | -502.02% | 108.60% | -146.20% | 347.72% | -94.70% |
| Foreign Exchange rate Adjustments | 541.67% | -125.81% | 123.13% | -491.18% | -101.57% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -125.74% | 273.04% | -142.42% | 370.15% | -246.60% |